Last reviewed · How we verify
NBTXR3
At a glance
| Generic name | NBTXR3 |
|---|---|
| Sponsor | Nanobiotix |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer (PHASE1)
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (PHASE3)
- A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE1)
- NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (PHASE1)
- Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies (PHASE1, PHASE2)
- NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer (PHASE2)
- NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer (PHASE1, PHASE2)
- NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NBTXR3 CI brief — competitive landscape report
- NBTXR3 updates RSS · CI watch RSS
- Nanobiotix portfolio CI